Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988732 | 0.91 | P2RX7 (0.47) | TSHRALDH1A1ALOX12P2RX7MEN1 | |
| SCHEMBL4988064 | 0.91 | ALDH1A1 (0.47) | TSHRALDH1A1ALOX12P2RX7MEN1 | |
| SCHEMBL14272291 | 0.89 | TSHR (0.54) | TSHRALDH1A1P2RX7EPHX2ALOX5 | |
| SCHEMBL4992054 | 0.89 | P2RX7 (0.46) | TSHRALDH1A1ALOX12P2RX7MEN1 | |
| SCHEMBL13532457 | 0.88 | EPHX2 (0.40) | TSHRALDH1A1ALOX12EPHX2ALOX5 | |
| SCHEMBL4982846 | 0.88 | GRM5 (0.41) | TSHRALDH1A1ALOX12P2RX7EPHX2 | |
| SCHEMBL4982679 | 0.86 | TSHR (0.43) | TSHRALDH1A1P2RX7EPHX2ALOX5 | |
| SCHEMBL4988062 | 0.85 | ALDH1A1 (0.42) | TSHRALDH1A1ALOX12P2RX7MEN1 | |
| SCHEMBL4985425 | 0.85 | TSHR (0.44) | TSHRALDH1A1ALOX12P2RX7MEN1 | |
| SCHEMBL4990489 | 0.83 | TSHR (0.41) | TSHRP2RX7EPHX2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| EP-1860942-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2007-12-05 | — | — | EP | claimed |
| WO-2006102610-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | TSHR 3850/4885ALDH1A1 3640/4885ALOX12 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.